Pruritus - Pipeline Insight, 2022

DelveInsight’s, “Pruritus – Pipeline Insight, 2022,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Pruritus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage
Pruritus Understanding
Pruritus: Overview

Pruritus Emerging Drugs Chapters
This segment of the Pruritus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pruritus Emerging Drugs
HSK21542: Haisco Pharmaceuticals
HSK 21542 is a small molecule, peripheral kappa receptor agonist, being developed by Sichuan Haisco Pharmaceutical Group for the treatment of pruritus in Phase III stage of development.
Linerixibat: GalaxoSmithKline
Linerixibat is an investigational product for the treatment of cholestatic pruritus in patients with PBC and it is not currently approved for use anywhere in the world. In 2019, FDA granted orphan drug designation for linerixibat in the treatment of PBC and associated cholestatic pruritus. Linerixibat is a minimally absorbed small molecule inhibitor of IBAT administered as an oral tablet. By blocking resorption of bile acids in the small intestine, linerixibat reduces pruritic bile acids in circulation. Currently it is being evaluated in Phase III clinical trial to treat patients with pruritus.
Further product details are provided in the report……..
Pruritus: Therapeutic Assessment
This segment of the report provides insights about the different Pruritus drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Pruritus
There are approx. 25+ key companies which are developing the therapies for Pruritus. The companies which have their Pruritus drug candidates in the mid to advanced stage, i.e. Phase III include, Haisco Pharmaceuticals.
Phases
DelveInsight’s report covers around 25+ products under different phases of clinical development like
Late-stage products (Phase III )
Mid-Stage products (Phase II)
Early-stage products ( Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Pruritus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Oral
Molecule Type

Products have been categorized under various Molecule types such as
Small molecules
Peptide
Antibiotics
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pruritus: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pruritus therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pruritus drugs.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Pruritus R&D. The therapies under development are focused on novel approaches to treat/improve Pruritus.
Pruritus Report Insights
Pruritus Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs
Pruritus Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Pruritus drugs?
How many Pruritus drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pruritus?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pruritus therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Pruritus and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players
GlaxoSmithKline
Haisco Pharmaceutical
Galderma
Trevi Therapeutics
Kiniksa Pharmaceuticals
Avior
MC2 therapeutics
Regenron/ Sanofi
AOBiome LLC
Pfizer
Lumosa Therapeutics
Jiangsu HengRui Medicine
Escient Pharmaceuticals
Asana BioSciences
Clexio Bioscineces
Forte Biosciences
Kissei Pharmaceutical
Evax AG
BioMimetix
Mirium Pharma
Cara Therapeutics
Mallinckrodt
Vanda Pharmaceuticals
Titan Pharmaceuticals
Hepagene Therapeutics
Tioga Pharmaceuticals

Key Products
Linerixibat
HSK21542
Nemolizumab
Nalbuphine
Vixarelimab
AV104
Dupilumab
B244
Abrocitinib
LT5001
SHR0410
EP547
ASN008
CLE-400
BMX-010
FB-401
Research programme: anti-pruritus therapeutics
Tradipitant
TP 2021
HPG-9399

Companies

GlaxoSmithKline
Haisco Pharmaceutical
Galderma
Trevi Therapeutics
Kiniksa Pharmaceuticals
Avior
MC2 therapeutics
Regenron/ Sanofi
AOBiome LLC
Pfizer
Lumosa Therapeutics
Jiangsu HengRui Medicine
Escient Pharmaceuticals
Asana BioSciences
Clexio Bioscineces
Forte Biosciences
Kissei Pharmaceutical
Evax AG
BioMimetix
Mirium Pharma
Cara Therapeutics
Mallinckrodt
Vanda Pharmaceuticals
Titan Pharmaceuticals
Hepagene Therapeutics
Tioga Pharmaceuticals